A Study To Evaluate Nyx-458 In Subjects With Mild Cognitive Impairment Associated With Parkinson's Disease
Posted Date: Jan 14, 2020
- Investigator: Michael Keys
- Specialties: Memory Disorders, Movement Disorders, Parkinson's Disease
- Type of Study: Drug
The objective of the study is to evaluate the safety and tolerability of multiple dose levels of NYX- 458 in subjects with mild cognitive impairment associated with Parkinson’s disease (MCI-PD), and to explore the potential benefit of NYX-458 on cognition
Criteria:
50 To 80 Years Of Age, Diagnosis Of Parkinson’S Disease, And Diagnosis Of Mild Cognitive Impairment Associated With Parkinson’S Disease
Keywords:
Parkinsons, Mild Cognitive Impairment
For More Information:
Marcelle Shidler, Ma
513-558-2455
shidlemd@ucmail.uc.edu